Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American …
SD Silberstein, S Holland, F Freitag, DW Dodick… - Neurology, 2012 - AAN Enterprises
Objective: To provide updated evidence-based recommendations for the preventive
treatment of migraine headache. The clinical question addressed was: What pharmacologic …
treatment of migraine headache. The clinical question addressed was: What pharmacologic …
Narrative review: reversible cerebral vasoconstriction syndromes
LH Calabrese, DW Dodick, TJ Schwedt… - Annals of internal …, 2007 - acpjournals.org
Reversible cerebral vasoconstriction syndromes (RCVS) comprise a group of diverse conditions,
all characterized by reversible multifocal narrowing of the cerebral arteries heralded by …
all characterized by reversible multifocal narrowing of the cerebral arteries heralded by …
A phase‐by‐phase review of migraine pathophysiology
DW Dodick - Headache: the journal of head and face pain, 2018 - Wiley Online Library
… Dodick has provided consultation, within the past 5 years, to Acorda, Allergan, Amgen, Alder,
Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, …
Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, …
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
HC Diener, DW Dodick, SK Aurora, CC Turkel… - …, 2010 - journals.sagepub.com
Objectives: This is the second of a pair of studies designed to evaluate the efficacy and
safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic …
safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic …
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
SK Aurora, DW Dodick, CC Turkel, RE DeGryse… - …, 2010 - journals.sagepub.com
Objectives: This is the first of a pair of studies designed to assess efficacy, safety and
tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic …
tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic …
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
…, JH Noseworthy, CF Lucchinetti, DW Dodick… - Annals of …, 1999 - Wiley Online Library
There are no established treatments for patients with acute, severe neurological deficits
caused by multiple sclerosis or other inflammatory demyelinating diseases of the central …
caused by multiple sclerosis or other inflammatory demyelinating diseases of the central …
OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double‐blind, randomized, placebo‐controlled phases of the PREEMPT clinical …
DW Dodick, CC Turkel, RE DeGryse… - … : The Journal of …, 2010 - Wiley Online Library
(Headache 2010;50:921‐936) Objective.— To assess the efficacy, safety, and tolerability of
onabotulinumtoxinA (BOTOX ® ) as headache prophylaxis in adults with chronic migraine. …
onabotulinumtoxinA (BOTOX ® ) as headache prophylaxis in adults with chronic migraine. …
[HTML][HTML] Fremanezumab for the preventive treatment of chronic migraine
SD Silberstein, DW Dodick, ME Bigal… - … England Journal of …, 2017 - Mass Medical Soc
Background Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene–related
peptide (CGRP), is being investigated as a preventive treatment for migraine. We …
peptide (CGRP), is being investigated as a preventive treatment for migraine. We …
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a …
TW Ho, MD Ferrari, DW Dodick, V Galet, J Kost, X Fan… - The Lancet, 2008 - thelancet.com
Background Calcitonin gene-related peptide (CGRP) probably has a role in migraine
pathophysiology, and antagonism of its receptors might provide treatment without the …
pathophysiology, and antagonism of its receptors might provide treatment without the …
Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial
VL Stauffer, DW Dodick, Q Zhang, JN Carter… - JAMA …, 2018 - jamanetwork.com
… Dr Dodick has received compensation from serving on advisory boards and/or consulting
within the past 5 years for Allergan, Amgen, Novartis, Alder, Arteaus, Pfizer, Colucid, Merck, …
within the past 5 years for Allergan, Amgen, Novartis, Alder, Arteaus, Pfizer, Colucid, Merck, …
